Neurocrine initiates Phase 1 study of NBIP-‘2118

Neurocrine (NBIX) Biosciences announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-‘2118 in adult participants. NBIP-‘2118 is an investigational corticotropin-releasing factor type 2 receptor peptide agonist and a potential first-in-class therapy for obesity. The Phase 1 study initially will evaluate the safety and tolerability of single ascending doses of NBIP-‘2118 compared to placebo in healthy-weight adult participants, as well as those who are overweight or obese. Initial data is expected in 2027.